In line with these observations, Ahn and coworkers have explored a large group of 272 patients that were surgically treated for ER+ breast cancer: 10.3% of these tumors was TP53-mutated; TP53 mutation rate was significantly higher in low-PR tumors than in high-PR tumors (17.1% vs 7.9%); and, low-PR tumors displayed a dysregulated glucose metabolism (as evidenced by 18F-FDG PET) and an adverse impact on recurrence-free survival [328]. The gene discussed is TP53; the disease is breast cancer.